1
|
Magnani JW and Dec GW: Myocarditis:
current trends in diagnosis and treatment. Circulation.
113:876–890. 2006. View Article : Google Scholar : PubMed/NCBI
|
2
|
Feldman AM and McNamara D: Myocarditis. N
Engl J Med. 343:1388–1398. 2000. View Article : Google Scholar
|
3
|
Amabile N, Fraisse A, Bouvenot J, et al:
Outcome of acute fulminant myocarditis in children. Heart.
92:1269–1273. 2006. View Article : Google Scholar : PubMed/NCBI
|
4
|
Ichikawa R, Sumitomo N, Komori A, et al:
The follow-up evaluation of electrocardiogram and arrhythmias in
children with fulminant myocarditis. Circ J. 75:932–938. 2011.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Wolf HM and Eibl MM: Immunomodulatory
effect of immunoglobulins. Clin Exp Rheumatol. 14(Suppl 15):
S17–S25. 1996.
|
6
|
Rosen FS: Putative mechanisms of the
effect of intravenous gamma-globulin. Clin Immunol Immunopathol.
67:S41–S43. 1993. View Article : Google Scholar : PubMed/NCBI
|
7
|
Kawai C: From myocarditis to
cardiomyopathy: mechanisms of inflammation and cell death: learning
from the past for the future. Circulation. 99:1091–1100. 1999.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Yu Z and Lennon VA: Mechanism of
intravenous immune globulin therapy in antibody-mediated autoimmune
diseases. N Engl J Med. 340:227–228. 1999. View Article : Google Scholar : PubMed/NCBI
|
9
|
Drucker NA, Colan SD, Lewis AB, et al:
Gamma-globulin treatment of acute myocarditis in the pediatric
population. Circulation. 89:252–257. 1994. View Article : Google Scholar : PubMed/NCBI
|
10
|
Mason JW, O’Connell JB, Herskowitz A, et
al: A clinical trial of immunosuppressive therapy for myocarditis.
The Myocarditis Treatment Trial Investigators. N Engl J Med.
333:269–275. 1995. View Article : Google Scholar : PubMed/NCBI
|
11
|
Weller AH, Hall M and Huber SA: Polyclonal
immunoglobulin therapy protects against cardiac damage in
experimental coxsackievirus-induced myocarditis. Eur Heart J.
13:115–119. 1992.
|
12
|
Newburger JW, Sanders SP, Burns JC, et al:
Left ventricular contractility and function in Kawasaki syndrome.
Effect of intravenous gamma-globulin. Circulation. 79:1237–1246.
1989. View Article : Google Scholar : PubMed/NCBI
|
13
|
O’Connell JB, Robinson JA, Henkin RE and
Gunnar RM: Immunosuppressive therapy in patients with congestive
cardiomyopathy and myocardial uptake of gallium-67. Circulation.
64:780–786. 1981.PubMed/NCBI
|
14
|
Anderson JL, Fowles RE, Unverferth DV, et
al: Immunosuppressive therapy of myocardial inflammatory disease.
Initial experience and future trials to define indications for
therapy. Eur Heart J. 8(Suppl): 263–266. 1987. View Article : Google Scholar
|
15
|
Kishimoto C, Takamatsu N, Kawamata H, et
al: Immunoglobulin treatment ameliorates murine myocarditis
associated with reduction of neurohumoral activity and improvement
of extracellular matrix change. J Am Coll Cardiol. 36:1979–1984.
2000. View Article : Google Scholar
|
16
|
McNamara DM, Rosenblum WD, et al:
Intravenous immune globulin in the therapy of myocarditis and acute
cardiomyopathy. Circulation. 95:2476–2478. 1997. View Article : Google Scholar : PubMed/NCBI
|
17
|
Gullestad L, Aass H, Fjeld JG, et al:
Immunomodulating therapy with intravenous immunoglobulin in
patients with chronic heart failure. Circulation. 103:220–225.
2001. View Article : Google Scholar : PubMed/NCBI
|
18
|
Takeda Y, Yasuda S, Miyazaki S, et al:
High-dose immunoglobulin G therapy for fulminant myocarditis. Jap
Circ J. 62:871–872. 1998. View Article : Google Scholar : PubMed/NCBI
|
19
|
Nigro G, Bastianon V, Colloridi V, et al:
Human parvovirus B19 infection in infancy associated with acute and
chronic lymphocytic myocarditis and high cytokine levels: report of
3 cases and review. Clin Infect Dis. 31:65–69. 2000. View Article : Google Scholar : PubMed/NCBI
|
20
|
Tsai YG, Ou TY, Wang CC, et al:
Intravenous gamma-globulin therapy in myocarditis complicated with
complete heart block: report of one case. Acta Paediatr Taiwan.
42:311–313. 2001.PubMed/NCBI
|
21
|
Shioji K, Matsuura Y, Iwase T, et al:
Successful immunoglobulin treatment for fulminant myocarditis and
serial analysis of serum thiredoxin: a case report. Circ J.
66:977–980. 2002. View Article : Google Scholar : PubMed/NCBI
|
22
|
Tedeschi A, Airaghi L, Giannini S, et al:
High-dose intravenous immunoglobulin in the treatment of acute
myocarditis. A case report and review of the literature. J Intern
Med. 251:169–173. 2002. View Article : Google Scholar : PubMed/NCBI
|
23
|
Stouffer GA, Sheahan RG, Lenihan DJ, et
al: The current status of immune modulating therapy for
myocarditis: a case of acute parvovirus myocarditis treated with
intravenous immunoglobulin. Am J Med Sci. 326:369–374. 2003.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Kim HS, Sohn S, Park JY and Seo JW:
Fulminant myocarditis successfully treated with high-dose
immunoglobulin. Int J Cardiol. 96:485–486. 2004. View Article : Google Scholar : PubMed/NCBI
|
25
|
Braun JP, Schneider M, Dohmen P and
Döpfmer U: Successful treatment of dilative cardiomyopathy in a
12-year-old girl using the calcium sensitizer levosimendan after
weaning from mechanical biventricular assist support. J
Cardiothorac Vasc Anest. 18:772–774. 2004.
|
26
|
Abe S, Okura Y, Hoyano M, et al: Plasma
concentrations of cytokines and neurohumoral factors in a case of
fulminant myocarditis successfully treated with intravenous
immunoglobulin and percutaneous cardiopulmonary support. Circ J.
68:1223–1226. 2004. View Article : Google Scholar
|
27
|
English RF, Janosly JE, Ettedgui JA and
Webber SA: Outcomes for children with acute myocarditis. Cardiol
Young. 14:488–493. 2004. View Article : Google Scholar : PubMed/NCBI
|
28
|
Karaaslan S, Oran B, Caliskan U, et al:
Hemolysis after administration of high-dose immunoglobulin in a
patient with myocarditis. Turk J Haematol. 20:237–240. 2003.
|
29
|
Khan MA, Das B, Lohe A and Sharma J:
Neonatal myocarditis presenting as an apparent life threatening
event. Clin Pediatr (Phila). 42:649–652. 2003. View Article : Google Scholar : PubMed/NCBI
|
30
|
Robinson JL, Hartling L, Crumley E, et al:
A systematic review of intravenous gamma globulin for therapy of
acute myocarditis. BMC Cardiovascular Disorders. 5:122005.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Kishimoto C, Shioji K, Kinoshita M, et al:
Treatment of acute inflammatory cardiomyopathy with intravenous
immunoglobulin ameliorates left ventricular function associated
with suppression of inflammatory cytokines and decreased oxidative
stress. Intern J Cardiol. 91:173–178. 2003. View Article : Google Scholar
|
32
|
Wang CY, Li Lu F, Wu MH, et al: Fatal
coxsackievirus A16 infection. Pediatr Infect Dis J. 23:275–276.
2004. View Article : Google Scholar
|
33
|
McNamara DM, Holubkov R, Starling RC, et
al: Controlled trial of intravenous immune globulin in recent-onset
dilated cardiomyopathy. Circulation. 103:2254–2259. 2001.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Finkel MS, Oddis CV, Jacob TD, et al:
Negative inotropic effects of cytokines on the heart mediated by
nitric oxide. Science. 257:387–389. 1992. View Article : Google Scholar : PubMed/NCBI
|
35
|
Leung DY, Burns JC, Newburger JW and Geha
RS: Reversal of lymphocyte activation in vivo in Kawasaki syndrome
by intravenous gammaglobulin. J Clin Invest. 79:468–472. 1987.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Hosenpud JD, Campbell SM and Mendelson DJ:
Interleukin-1-induced myocardial depression in an isolate beating
heart preparation. J Heart Transplant. 8:460–464. 1989.PubMed/NCBI
|